Ajou University repository

Impact of metformin on statin-associated myopathy risks in dyslipidemia patientsoa mark
  • Bak, Keunhyeong ;
  • Moon, Suhyeon ;
  • Ko, Minjung ;
  • Choi, Yeo Jin ;
  • Shin, Sooyoung
Citations

SCOPUS

2

Citation Export

Publication Year
2023-08-01
Journal
Pharmacology Research and Perspectives
Publisher
John Wiley and Sons Inc
Citation
Pharmacology Research and Perspectives, Vol.11 No.4
Keyword
drug interactionsmetforminmyopathystatin
Mesh Keyword
Cohort StudiesDyslipidemiasHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypoglycemic AgentsMetforminMuscular DiseasesRetrospective Studies
All Science Classification Codes (ASJC)
NeurologyPharmacology, Toxicology and Pharmaceutics (all)
Abstract
A growing number of patients with metabolic disorders are receiving statin and antidiabetic therapies as comedications. A signal of increased risk of myotoxicity due to potential interactions between antidiabetics and statins has been detected in previous studies. To investigate the effects of metformin on myopathy risks when added to preexisting statin therapy in dyslipidemia patients, we performed a retrospective cohort study using the Korean national health insurance data in statin-treated dyslipidemia patients with or without concomitant metformin use. We compared the risk of myopathy in statin + metformin users against statin-only users. Hazard ratios (HRs) and 95% confidence intervals (CIs) have been calculated following propensity score (PS) matching between study groups and subsequent stratification per patient factors. We included 4092 and 8161 patients in PS-matched statin + metformin and statin-only groups, respectively. The risk of myopathy decreased when metformin was used together with statins (adjusted HR 0.84; 95% CI 0.71–0.99). In subgroup analyses per individual statin agent and in stratified risk analyses, no specific statin agents or patient factors were associated with statistically significant myopathy risk. This study found that a comedication with metformin was associated with decreased myopathy risk in statin-treated dyslipidemia patients compared to statin-only users. Our findings suggest that metformin may provide protective effects on potential muscle toxicities induced by statin therapy.
ISSN
2052-1707
Language
eng
URI
https://aurora.ajou.ac.kr/handle/2018.oak/33512
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85164265896&origin=inward
DOI
https://doi.org/10.1002/prp2.1114
Journal URL
http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)2052-1707
Type
Article
Funding
This study was supported by Ajou University Research Fund (S\u20102022\u2010G0001\u201000245) and by Basic Science Research Program through the National Research Foundation of Korea (NRF) grants funded by the Ministry of Science and ICT (no. 2021R1C1C1003735), Ministry of Education (no. 2021R1I1A1A01044500), and the Ministry of Food and Drug Safety (no. 21153MFDS602). The study findings does not represent the Korean Health Insurance Review & Assessment Service (HIRA)'s opinions.
Show full item record

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Shin, Soo Young  Image
Shin, Soo Young 신수영
Division of Pharmacy Sciences
Read More

Total Views & Downloads

File Download

  • There are no files associated with this item.